---
search:
  boost: 3
---

# Parkinson's Agents

This is a subcategory of Central Nervous System (CNS) Agents.

## Decision Trees

- [CNS - Parkinson's Agents - Non-Preferred - Apokyn, Inbrija, Kynmobi, Nourianz](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBURjNDM1M2TDg5Njk5TlQ3U1pOWVNMSEpLSCQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [CNS - Parkinson's Agents - Carbidopa/Levodopa Dispersible Tab, Carbidopa/Levodopa/Entacapone, Gocovri, Ongentys, Osmolex ER, Pramipexole ER, Rasagiline, Ropinirole ER, Rytary, Tolcapone, Xadago, Zelapar](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQTBKVEMwWVhMVE9UWDBPRUVHSjFBWloxSCQlQCN0PWcu){ :target="_blank" rel="noopener"}

- [CNS - Parkinson's Agents - Neurpo](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUM0lJRzBHUlpTNjhUVEZaSkJHN0lLN0ZKNyQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred            | Generic Name | Quantity | Time (Days) |
| :------------------- | :----------- | :------: | :---------: |
| Amantadine           |              |          |             |
| Carbidopa            |              |          |             |
| Carbidopa/Levodopa |              |          |             |
| Entacapone           |              |          |             |
| Pramipexole          |              |          |             |
| Ropinirole           |              |          |             |
| Selegiline           |              |          |             |

### Non-Preferred

| Non-Preferred                        | Generic Name | Quantity | Time (Days) |
| :----------------------------------- | :----------- | :------: | :---------: |
| Apokyn                               |              |          |             |
| Carbidopa / Levodopa Dispersible Tab |              |          |             |
| Carbidopa / Levodopa / Entacapone    |              |          |             |
| Gocovri                              |              |          |             |
| Inbrija                              |              |          |             |
| Kynmobi                              |              |          |             |
| Neupro                               |              |          |             |
| Nourianz                             |              |          |             |
| Ongentys                             |              |          |             |
| Osmolex ER                           |              |          |             |
| Pramipexole ER                       |              |          |             |
| Rasagiline                           |              |          |             |
| Ropinirole ER                        |              |          |             |
| Rytary                               |              |          |             |
| Tolcapone                            |              |          |             |
| Xadago                               |              |          |             |
| Zelapar                              |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^30 days^^ with at least ^^one preferred^^ drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Apomorphine (Apokin/Kynmobi), Levodopa Inhalation (Inbrija), & Istradefylline (Nourianz)

Additional Apomorphine (Apokin/Kynmobi), Levodopa Inhalation (Inbrija), & Istradefylline (Nourianz) Criteria

- Must have had inadequate clinical response to at least ^^30 days^^ with one other drug for the treatment of “off episodes” (dopamine agonist, COMT inhibitor, or MAO-B inhibitor)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=39&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"} </br>
[Criteria](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20criteria%20effective%2001.01.2024.pdf#page=45){ :target="_blank" rel="noopener"} </br>
[Preferred Drug List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20effective%2001.01.2024.pdf#page=18){ :target="_blank" rel="noopener"} </br>
[Quantity Limit List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/Quantity%20Limits.pdf){ :target="_blank" rel="noopener"}
